NVS (Novartis) Future Price to Earnings

Brandmark of Novartis AG (NVS)

The industry trend is shifting toward high-precision gene therapy for DNA correction, a field where Novartis AG (NVS) is a leader. The company's forward P/E ratio reflects the asset's value dynamics, where 16.20 represents the current metric level. Stable management is focused on high-margin platforms, complementing this with the implementation of environmental standards and carbon-neutral production.

Future Price to Earnings: novartis.com (NVS) for 07/04/2022 - 11/14/2026

Analytical breakdowns and data insights for company novartis.com (NVS)

- stock quotes and analyst forecast:
Stock Price Novartis Inc.|NVS - Fair Value Consensus
- business market valuation indicators:
Market Value Novartis Corporation|NVS - Total Enterprise Value
- balance sheet equity data:
Net Assets per Single Share Novartis|NVS - Company Book Value|Market Capitalization to Book Value Ratio novartis.com|NVS - Total Business Assets
- debt level and financial liquidity data:
Total Debt to Capital Novartis AG|NVS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Novartis Inc.|NVS - Company Aggregate Debt|Debts to Book Capitalization Novartis Pharma|NVS - Long-Term Indebtedness|Company Short-Term Debt Novartis|Quick Liquidity novartis.com
- company profitability and valuation multiples indicators:
NVS - Company Net Income|Future Profit Novartis AG|NVS - Price to Earnings Ratio|Forward P/E Multiple Novartis Pharma|NVS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Novartis|NVS - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Novartis|NVS - Earnings per share for the last four quarters|Quarterly EPS earnings growth novartis.com|NVS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Novartis AG
- issuer revenue and sales details:
NVS - Company Gross Revenue|Company Future Sales Volume Novartis Inc.|NVS - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Novartis Inc.
Summary company analytics:Novartis Corporation
Brand item of Novartis AG

The forward P/E reflects the market value of shares relative to the projected net income for the coming period. For Novartis AG (NVS), this calculation verifies the efficiency of R&D expenditures amid pressure from generics. By analyzing the issuer's expected P/E, an investor assesses the market's willingness to pay a premium for innovative molecules. An increase in this metric signals optimism regarding new patents, while the stability of the metric confirms the business's resilience to competition.

Competitor analysis

Forward P/E Multiple LLY|ABBV (Abbvie) - Future Price to Earnings Multiple|Future Price to Earnings AstraZeneca Plc AZN|merck.com (MRK) - Projected Price to Earnings Ratio|NVO - Future Price to Earnings|Projected Price to Earnings Ratio Amgen Corp|PFE: Forward P/E Multiple|Price to Future Earnings Ratio SNY|BMY (bms.com) - Forward P/E Multiple|gsk.com (GSK) - Market Cap to Projected Earnings|Future Price to Earnings Takeda Pharmaceutical Company Limited (TAK)|Market Cap to Projected Earnings Teva Pharma|Forward P/E Multiple RDY (Dr. Reddy's Laboratories Limited)|VTRS: Price to Future Earnings Ratio|Roivant Corp - Forward P/E Multiple|Forward Price to Earnings Multiple Zai Lab (ZLAB)|BHC: Forward P/E Multiple|Projected Price to Earnings Cosmos Health, Inc.